Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults

Conditions

• Prurigo Nodularis

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Study Details

The main aim of this study is to assess real-world effectiveness of nemolizumab in Prurigo nodularis (PN) as measured by investigator and patient reported outcome (PRO) in clinical practice at Month 6.

Key Dates

Start date

Aug 11, 2025

Status verified

Aug 2025

Primary completion

Nov 30, 2027

Completion

Nov 30, 2027

Study Design

Enrollment

600 participants (estimated)

Arms

• Arm: Nemolizumab
  Participants with moderate-to-severe PN who are receiving nemolizumab (Nemluvio®) in routine clinical practice will be observed for approximately 12 months.

Primary Outcome Measure

Investigator Global Assessment-chronic Prurigo (IGA-CPG stage) at Month 6 [ Time Frame: At 6 month ]

Central Contacts

• Galderma Research and Development
  817-961-5000
  [email protected]

Locations (39)

Find similar trials in Birmingham, AL

Related Studies

• A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
  PHASE3 · Recruiting · Sanofi · Palo Alto, California